2023
DOI: 10.1002/phar.2867
|View full text |Cite
|
Sign up to set email alerts
|

Baricitinib versus tocilizumab in critically ill COVID‐19 patients: A retrospective cohort study

Grace M. Conroy,
Seth R. Bauer,
Andrea M. Pallotta
et al.

Abstract: BackgroundTocilizumab and baricitinib improve outcomes in severely ill patients with coronavirus disease 2019 (COVID‐19), however, comparative analyses of clinical outcomes related to these agents is lacking. A tocilizumab national shortage shifted treatment to baricitinib in critically ill patients, allowing for an outcome comparison in a similar population. The purpose of this study is to compare clinical outcomes in critically ill COVID‐19 patients who received tocilizumab and those who received baricitinib… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 38 publications
0
0
0
Order By: Relevance